Novo Nordisk reports topline data from Phase Ib/IIa trial of weight loss therapy
Amycretin’s safety profile reportedly aligns with that of other incretin-based therapies.
27 January 2025
27 January 2025
Amycretin’s safety profile reportedly aligns with that of other incretin-based therapies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.